Mesoblast Ltd (ASX:MSB) is a developer of allogeneic, or off-the-shelf, cellular medicines for severe inflammatory conditions. Its product RYONCIL (remestemcel-L-rknd) is the first FDA-approved mesenchymal stromal cell therapy, for steroid-refractory acute graft versus host disease (SR-aGvHD) in children. Mesoblast is also developing rexlemestrocel-L for chronic low back pain and heart failure. The company is listed on the ASX and Nasdaq and reports in US dollars. Dr Silviu Itescu is Chief Executive.

On 2 October 2026, Mesoblast shares were trading at $2.04 on the ASX, down 1.45%. Its full-year results, released in August, covered the first full year of RYONCIL's US launch.

Recent Developments

On 27 August 2026 (Australian time), Mesoblast reported its results for the year ended 30 June 2026. Figures are in US dollars. Key points include:

  • Total Revenue was US$120.3 million, up from US$17.2 million.
  • RYONCIL generated net revenue of US$115.2 million after a gross-to-net adjustment of 13.4%.
  • Reported Gross Profit was US$103.6 million.
  • The net loss narrowed by 44% to US$57.5 million, with a second-half loss of US$17.3 million.
  • Net operating cash spend was US$43.8 million.
  • Cash was US$103 million, and the company entered a US$125.0 million five-year Credit facility.

Mesoblast said more than 50 pediatric transplant centres had been onboarded since launch, including 14 of the 15 largest, and payer coverage extended to more than 280 million covered lives. Median time from patient identification to treatment fell from 29 days to 8 days. Dr Itescu said the company plans to expand RYONCIL use to adults with severe SR-aGvHD, a market three times larger than the pediatric market. Data presented in February 2026 showed 76% Day 100 survival in adolescents and adults treated with RYONCIL for third-line SR-aGvHD, and a registration trial in adults has commenced.

In its back pain program, Mesoblast completed treatment of 350 patients in the Phase 3 trial of rexlemestrocel-L for chronic low back pain, with top-line results expected in mid-CY2027. It received IND clearance for a registrational trial of RYONCIL in children with Duchenne muscular dystrophy and requested a modular BLA review for rexlemestrocel-L in heart failure patients with left ventricular assist devices. The company also unveiled next-generation CAR-MSC and oncolytic virus programs.

Research and development expense increased by US$39.7 million after adjusting for a prior-period inventory benefit, reflecting product development across both platforms, Phase 3 trials and regulatory filings. Selling, general and administration expenses were US$57.3 million. Mesoblast said the credit Facility consolidated and retired two higher-cost facilities. The Phase 3 back pain trial was expanded from 300 to 350 patients due to Demand from trial investigators. The company noted chronic low back pain affects more than 7 million people in the US and represents a total addressable market of more than US$10 billion. It also licensed an oncolytic virus technology platform from Baylor College of Medicine.

Sector Context

Cell therapies are an emerging area of medicine, with potential to treat conditions where conventional drugs have limited effect. However, they face complex manufacturing, regulatory and reimbursement requirements. Gaining FDA approval is a significant milestone, but commercial success depends on hospital adoption and payer coverage.

Biotechnology companies transitioning to commercial operations often continue to incur losses as they invest in sales infrastructure and further trials. Label expansions into larger patient populations can increase revenue potential but require additional clinical evidence.

Graft versus host disease is a serious complication of bone marrow transplants, and treatment Options for steroid-refractory cases are limited. Expanding into adult patients and earlier lines of therapy can significantly increase the addressable market for approved therapies.

Cell therapy Manufacturing requires specialised facilities and quality controls, and companies that can produce therapies at industrial scale with consistent release criteria may have an advantage. Reimbursement for high-cost therapies often requires negotiation with commercial and government payers, which can affect the pace of adoption. Mesoblast has also established commercial partnerships in Japan, Europe and China.

Risks and Uncertainties

Mesoblast remains loss-making and depends on RYONCIL sales and financing to fund operations. The adult SR-aGvHD trial and back pain Phase 3 trial may not succeed. Regulatory outcomes are uncertain. The company carries Debt under its credit facility, with finance costs of about US$23.8 million in FY26. Competition from other treatments and reimbursement changes could affect sales. Currency movements affect returns for ASX holders.

Accounts receivable rose significantly during the year, and the timing of cash collections may affect operating cash flow.

Catalysts Investors Can Watch

Investors may watch for RYONCIL sales growth, progress on the adult SR-aGvHD registration trial, the back pain trial readout in mid-2027, the outcome of the modular BLA review request, and progress on the Duchenne program.

Updates on CAR-MSC and oncolytic virus programs may also provide insight into longer-term pipeline opportunities.

Summing Up

Mesoblast's FY2026 result showed a large increase in revenue following RYONCIL's launch, a narrower loss and a refinanced debt position. Label expansion and clinical trial outcomes are likely to shape its outlook.

Its US$103 million cash position and credit facility provide funding as it advances its programs.